失眠患者使用精神类药物的药学风险评估与效果分析

Objective To evaluate the pharmaceutical risks associated with the combined use of Class II psychotropic drugs such as Estazolam, along with antibiotics and heat-clearing and detoxifying drugs, in insomnia patients, and to analyze the efficacy of pharmaceutical intervention. Methods A total of 60 insomnia patients admitted from January 2023 to January 2024 were selected. They were divided into a control group and an observation group, with 30 cases in each group, based on whether pharmaceutical interventions were implemented. The control group was given routine medication management, and the observation group was given systematic pharmaceutical intervention on the basis of the control group. The incidence of adverse reactions, the rational rate of medication and the improvement of sleep quality were compared between the two groups. Results Among the 60 patients receiving combined medication, 42 cases(70.00%) had potential risks of drug interactions, including 8 high-risk cases and 30 medium-risk cases. The incidence of adverse reactions in the observation group was 6.67%, which was lower than that in the control group(23.33%)(P<0.05). The rate of rational drug use in the observation group was 93.33%, higher than that in the control group(70.00%)(P<0.05). After treatment, the Pittsburgh Sleep Quality Index(PSQI) score in the observation group was significantly better than that in the control group(P<0.05). Conclusion The combined use of Class II psychotropic drugs psychotropic drugs with antibiotics and heat-clearing and detoxifying drugs in insomnia patients presents a relatively high pharmaceutical risk. Systematic pharmaceutical risk assessment and intervention can effectively reduce adverse reactions, enhance medication safety, and improve clinical efficacy.